The trastuzumab biosimilar market has emerged as a significant segment within the global biopharmaceutical industry. Trastuzumab, originally marketed under the brand name Herceptin by Roche, is an essential treatment for HER2-positive breast cancer and gastric cancer. As patents for the drug expired, biosimilars—medications that are highly similar but not identical to the reference...